Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Highnoon LaboratoriesKAR:HINOON -0.45%96 Net Margin % is 13.94% as of Mar. 2026, which is 7% above its 10-year median of 13.07. GuruFocus rates KAR:HINOON with a GF Score™ of 96/100 and a GF Value™ of ₨1,019.72 (Fairly Valued). The stock has 3 warning signs investors should review. Among 960 Drug Manufacturers companies, Highnoon Laboratories ranks better than 76.87% on this metric.
The historical rank and industry rank for Highnoon Laboratories's Net Margin % or its related term are showing as below:
KAR:HINOON'
s Net Margin % Range Over the Past 10 Years
Min: 9.76 Med: 13.07 Max: 15.63
Current: 14.32
KAR:HINOON's Net Margin % is ranked better than 76.87% of 960
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs KAR:HINOON: 14.32
Highnoon Laboratories (KAR:HINOON) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Highnoon Laboratories Net Margin % Related Terms
Highnoon Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Highnoon Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:HINOON vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Highnoon Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Highnoon Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Highnoon Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Highnoon Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Highnoon Laboratories (KAR:HINOON) has a Net Margin % of 13.94% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Highnoon Laboratories and its competitors. This is near median its historical median of 13.07. Over the past decade, Highnoon Laboratories' Net Margin % has ranged from 9.76 to 15.63. According to the industry distribution chart, Highnoon Laboratories ranks #222 out of 960 companies in the Drug Manufacturers industry, placing it in the top 23.1%.
Is Highnoon Laboratories' Net Margin % too high?
Highnoon Laboratories' current Net Margin % of 13.94% is near median its 10-year median of 13.07. Over the past 10 years, this metric has ranged from a low of 9.76 to a high of 15.63. The Drug Manufacturers industry median Net Margin % is 5.56. Highnoon Laboratories' value of 13.94% is 150.7% above this industry median. Based on the distribution chart, Highnoon Laboratories ranks #222 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Highnoon Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Highnoon Laboratories' Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Highnoon Laboratories ranks #222 out of 960 companies for Net Margin %. This places Highnoon Laboratories in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Highnoon Laboratories' value of 13.94% is 150.7% above this benchmark. Historically, Highnoon Laboratories' own Net Margin % has ranged from 9.76 to 15.63 over the past decade. While the company's 10-year median is 13.07 vs. the industry median of 5.56, Highnoon Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Highnoon Laboratories's current Net Margin % of 13.94% is 150.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Highnoon Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Highnoon Laboratories's current Net Margin % is 13.94%, which is near median its own 10-year median of 13.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Highnoon Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Highnoon Laboratories (KAR:HINOON) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,019.72, compared to a current price of ₨961.21 — trading 5.7% below its estimated fair value. The current Net Margin % is 13.94%, which is near median its 10-year median of 13.07 and 150.7% above the Drug Manufacturers industry median of 5.56. Highnoon Laboratories' overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Highnoon Laboratories (KAR:HINOON), the current Net Margin % is 13.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Highnoon Laboratories (KAR:HINOON) Overvalued in 2026?
Based on GuruFocus' analysis, Highnoon Laboratories stock appears to be undervalued.
The current stock price of ₨961.21 is trading 5.7% below its estimated GF Value™ of ₨1,019.72.
GuruFocus considers Highnoon Laboratories to be Fairly Valued.
Key valuation signals for KAR:HINOON:
Net Margin %: 13.94% (near median its 10-year median of 13.07)
GF Value™: ₨1,019.72 vs. price of ₨961.21 (5.7% below fair value)
Industry Position: 150.7% above the Drug Manufacturers median (#222 of 960)
No single metric tells the full story. See the KAR:HINOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Highnoon Laboratories Ltd is a company engaged in the manufacture, import, sale, and marketing of pharmaceutical and allied consumer products. It focuses on the alimentary tract and metabolism, antihistamines, anti-infectives, cardiovascular, endocrine, hematology, musculoskeletal, nervous system, parasitology, respiratory, and urinary. Its products include AIRTAL (Aceclofenac); ARIA (ketotifen); ARTECXCIN, and artrodar (diacerein). Its other products include Asthavent, AXESOME, Bezisox, Betatec, and many more.
96GF Score
Get the complete analysis for KAR:HINOON
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HINOON has been successfully added to your 
